Logo image of BNR

BURNING ROCK BIOTECH LTD-ADR (BNR) Stock Fundamental Analysis

NASDAQ:BNR - Nasdaq - US12233L2060 - ADR - Currency: USD

8.37  +0.13 (+1.58%)

After market: 8.46 +0.09 (+1.08%)

Fundamental Rating

3

BNR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. BNR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BNR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BNR had negative earnings in the past year.
BNR had a negative operating cash flow in the past year.
In the past 5 years BNR always reported negative net income.
In the past 5 years BNR always reported negative operating cash flow.
BNR Yearly Net Income VS EBIT VS OCF VS FCFBNR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

The Return On Assets of BNR (-27.91%) is better than 69.60% of its industry peers.
BNR has a Return On Equity of -41.72%. This is in the better half of the industry: BNR outperforms 69.60% of its industry peers.
Industry RankSector Rank
ROA -27.91%
ROE -41.72%
ROIC N/A
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
BNR Yearly ROA, ROE, ROICBNR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Gross Margin of BNR (71.49%) is better than 82.37% of its industry peers.
BNR's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BNR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
BNR Yearly Profit, Operating, Gross MarginsBNR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

BNR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BNR remains at a similar level compared to 1 year ago.
The number of shares outstanding for BNR has been increased compared to 5 years ago.
There is no outstanding debt for BNR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BNR Yearly Shares OutstandingBNR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BNR Yearly Total Debt VS Total AssetsBNR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

BNR has an Altman-Z score of -5.11. This is a bad value and indicates that BNR is not financially healthy and even has some risk of bankruptcy.
BNR has a worse Altman-Z score (-5.11) than 60.43% of its industry peers.
There is no outstanding debt for BNR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.11
ROIC/WACCN/A
WACC8.25%
BNR Yearly LT Debt VS Equity VS FCFBNR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

A Current Ratio of 3.02 indicates that BNR has no problem at all paying its short term obligations.
BNR's Current ratio of 3.02 is on the low side compared to the rest of the industry. BNR is outperformed by 64.57% of its industry peers.
A Quick Ratio of 2.76 indicates that BNR has no problem at all paying its short term obligations.
BNR has a worse Quick ratio (2.76) than 65.29% of its industry peers.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.76
BNR Yearly Current Assets VS Current LiabilitesBNR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.08% over the past year.
BNR shows a small growth in Revenue. In the last year, the Revenue has grown by 0.53%.
BNR shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.21% yearly.
EPS 1Y (TTM)95.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.45%
Revenue 1Y (TTM)0.53%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%5.94%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 15.51% on average over the next years. This is quite good.
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BNR Yearly Revenue VS EstimatesBNR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
BNR Yearly EPS VS EstimatesBNR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNR. In the last year negative earnings were reported.
Also next year BNR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNR Price Earnings VS Forward Price EarningsBNR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNR Per share dataBNR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BNR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURNING ROCK BIOTECH LTD-ADR

NASDAQ:BNR (7/24/2025, 8:25:06 PM)

After market: 8.46 +0.09 (+1.08%)

8.37

+0.13 (+1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-06 2025-06-06
Earnings (Next)08-21 2025-08-21
Inst Owners38.48%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap85.87M
Analysts80
Price TargetN/A
Short Float %0.63%
Short Ratio0.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.17
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-3.39
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS7.12
BVpS7.78
TBVpS7.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.91%
ROE -41.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.49%
FCFM N/A
ROA(3y)-54.4%
ROA(5y)-43.17%
ROE(3y)-76.2%
ROE(5y)-58.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y-0.38%
F-Score5
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.02
Quick Ratio 2.76
Altman-Z -5.11
F-Score5
WACC8.25%
ROIC/WACCN/A
Cap/Depr(3y)26.43%
Cap/Depr(5y)152.99%
Cap/Sales(3y)5.44%
Cap/Sales(5y)15.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.45%
EPS Next Y-277.41%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.53%
Revenue growth 3Y0.52%
Revenue growth 5Y6.21%
Sales Q2Q%5.94%
Revenue Next Year48.35%
Revenue Next 2Y17.89%
Revenue Next 3Y16.85%
Revenue Next 5Y15.51%
EBIT growth 1Y65.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.24%
OCF growth 3YN/A
OCF growth 5YN/A